Details of the Drug

General Information of Drug (ID: DMTN5XI)

Drug Name

Chlordiazepoxide

Synonyms

Abboxide; Balance; Chloradiazepoxide; Chlordiazachel; Chlordiazepoxid; Chlordiazepoxidum; Chlordiazepoxydum; Chloridazepoxide; Chloridiazepide; Chloridiazepoxide; Chlorodiazepoxide; Chlozepid; Clopoxide; Clordiazepossido; Clordiazepoxido; Control; Decacil; Disarim; Eden; Elenium; Helogaphen; Ifibrium; Kalmocaps; Librelease; Librinin; Libritabs; Librium; Lygen; Menrium; Mesural; Methaminodiazepoxide; Mildmen; Multum; Napoton; Napton; Psicosan; Radepur; Risolid; Silibrin; Sonimen; Tropium; Viopsicol; Zeisin; Zetran; Chlordiazepoxide Base; Clordiazepossido [Italian]; A-Poxide; Apo-Chlordiazepoxide; Balance (pharmaceutical); Chlordiazepoxidum [INN-Latin]; Clordiazepoxido [INN-Spanish]; Eden-psich; Libritabs (TN); Librium (TN); MENRIUM 10-4; MENRIUM 5-4; Novapam (TN); Novo-Poxide; Tropium (TN); Chlordiazepoxide (JP15/USP/INN); Chlordiazepoxide [USAN:INN:BAN:JAN]; 3H-1,4-Benzodiazepin-2-amine, 7-chloro-N-methyl-5-phenyl, 4-oxide; 3H-1,4-Benzodiazepin-2-amine, 7-chloro-N-methyl-5-phenyl-, 4-oxide; 3H-1,4-Benzodiazepine, 7-chloro-2-(methylamino)-5-phenyl-, 4-oxide; 3H-1,4-benzodiazepin-2-amine,7-chloro-N-methyl-5-phenyl-,4-oxide; 7-Chlor-2-methylamino-5-phenyl-3H-1,4-benzodiazepin-4-oxid; 7-Chlor-2-methylamino-5-phenyl-3H-1,4-benzodiazepin-4-oxid [German]; 7-Chloro-2-(methylamino)-5-phenyl-3H-1,4-benzodiazepine 4-oxide; 7-Chloro-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-amine 4-oxide; 7-Cloro-2-metilamino-5-fenil-3H-1,4-benzodiazepina 4-ossido; 7-Cloro-2-metilamino-5-fenil-3H-1,4-benzodiazepina 4-ossido [Italian]; 7-chloro-4-hydroxy-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-imine

Indication

Disease Entry	ICD 11	Status	REF
Alcohol withdrawal	N.A.	Approved	[1]
Alcohol withdrawal delirium	N.A.	Approved	[1]
Anxiety	N.A.	Approved	[1]
Anxiety disorder	6B00-6B0Z	Approved	[2]
Irritable bowel syndrome	DD91.0	Approved	[1]
Peptic ulcer	DA61	Approved	[1]
Mixed anxiety and depressive disorder	N.A.	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Therapeutic Class

Antianxiety Agents

Affected Organisms

Humans and other mammals

ATC Code

N05BA02: Chlordiazepoxide

N05BA: Benzodiazepine derivatives

N05B: ANXIOLYTICS

N05: PSYCHOLEPTICS

N: NERVOUS SYSTEM

N05BA02: Chlordiazepoxide

N05BA: Benzodiazepine derivatives

N05B: ANXIOLYTICS

N05: PSYCHOLEPTICS

N: NERVOUS SYSTEM

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

299.75

Logarithm of the Partition Coefficient (xlogp)

2.4

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability: 99% of drug becomes completely available to its intended biological destination(s) [4]
Clearance: The drug present in the plasma can be removed from the body at the rate of 0.37 mL/min/kg [5]
Elimination: 0.5% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 24 - 48 hours [5]
Metabolism: The drug is metabolized via the hepatic []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 14.3 micromolar/kg/day [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.056% [5]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.25 L/kg [5]
Water Solubility: The ability of drug to dissolve in water is measured as 2 mg/mL [3]

Chemical Identifiers

Formula: C16H14ClN3O
IUPAC Name: 7-chloro-4-hydroxy-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-imine
Canonical SMILES: CN=C1CN(C(=C2C=C(C=CC2=N1)Cl)C3=CC=CC=C3)O
InChI: InChI=1S/C16H14ClN3O/c1-18-15-10-20(21)16(11-5-3-2-4-6-11)13-9-12(17)7-8-14(13)19-15/h2-9,21H,10H2,1H3
InChIKey: BUCORZSTKDOEKQ-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 2712
ChEBI ID: CHEBI:3611
CAS Number: 58-25-3
UNII: 6RZ6XEZ3CR
DrugBank ID: DB00475
TTD ID: D06BEP
ACDINA ID: D00120

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Translocator protein (TSPO)	TTPTXIN	TSPO_HUMAN	Modulator	[7]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Gene/Protein Processing	[8]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification

13 Disease of the digestive system

Disease Class

ICD-11: DD91 Irritable bowel syndrome

The Studied Tissue

Rectal colon tissue

The Studied Disease

Irritable bowel syndrome [ICD-11:DD91.0]

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Translocator protein (TSPO)	DTT	TSPO	1.60E-01	-0.64	-0.84

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Chlordiazepoxide (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sodium bicarbonate	DMMU6BJ	Minor	Altered absorption of Chlordiazepoxide due to GI dynamics variation caused by Sodium bicarbonate.	Acidosis [5C73]	[9]
Oliceridine	DM6MDCF	Major	Additive CNS depression effects by the combination of Chlordiazepoxide and Oliceridine.	Acute pain [MG31]	[10]
Voriconazole	DMAOL2S	Moderate	Decreased metabolism of Chlordiazepoxide caused by Voriconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[11]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Chlordiazepoxide caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[12]
Clarithromycin	DM4M1SG	Moderate	Decreased metabolism of Chlordiazepoxide caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[13]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Chlordiazepoxide caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[13]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Chlordiazepoxide caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[14]
Dihydrocodeine	DMB0FWL	Major	Additive CNS depression effects by the combination of Chlordiazepoxide and Dihydrocodeine.	Chronic pain [MG30]	[15]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Chlordiazepoxide and Olopatadine.	Conjunctiva disorder [9A60]	[16]
Propofol	DMB4OLE	Moderate	Additive cardiorespiratory depression effects by the combination of Chlordiazepoxide and Propofol.	Corneal disease [9A76-9A78]	[17]
Alfentanil	DMVO0UB	Major	Additive CNS depression effects by the combination of Chlordiazepoxide and Alfentanil.	Corneal disease [9A76-9A78]	[10]
Remifentanil	DMZTXCH	Major	Additive CNS depression effects by the combination of Chlordiazepoxide and Remifentanil.	Corneal disease [9A76-9A78]	[10]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Chlordiazepoxide and Ethanol.	Cystitis [GC00]	[18]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Chlordiazepoxide and Esketamine.	Depression [6A70-6A7Z]	[11]
SODIUM CITRATE	DMHPD2Y	Minor	Altered absorption of Chlordiazepoxide due to GI dynamics variation caused by SODIUM CITRATE.	Discovery agent [N.A.]	[9]
Mephenytoin	DM5UGDK	Moderate	Increased metabolism of Chlordiazepoxide caused by Mephenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[19]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Chlordiazepoxide caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[20]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Chlordiazepoxide caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[19]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Chlordiazepoxide caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[21]
Ethotoin	DMXWOCP	Moderate	Increased metabolism of Chlordiazepoxide caused by Ethotoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[19]
Carbamazepine	DMZOLBI	Moderate	Increased metabolism of Chlordiazepoxide caused by Carbamazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[22]
Cimetidine	DMH61ZB	Moderate	Decreased metabolism of Chlordiazepoxide caused by Cimetidine mediated inhibition of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[23]
Brimonidine	DMQLT4N	Moderate	Additive CNS depression effects by the combination of Chlordiazepoxide and Brimonidine.	Glaucoma [9C61]	[24]
Isoniazid	DM5JVS3	Moderate	Decreased metabolism of Chlordiazepoxide caused by Isoniazid mediated inhibition of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[25]
Rifampin	DMA8J1G	Minor	Increased metabolism of Chlordiazepoxide caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[26]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Chlordiazepoxide caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[27]
Didanosine	DMI2QPE	Minor	Altered absorption of Chlordiazepoxide due to GI dynamics variation caused by Didanosine.	Human immunodeficiency virus disease [1C60-1C62]	[9]
Amprenavir	DMLMXE0	Moderate	Decreased metabolism of Chlordiazepoxide caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[27]
Ritonavir	DMU764S	Moderate	Decreased metabolism of Chlordiazepoxide caused by Ritonavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[28]
Probenecid	DMMFWOJ	Minor	Decreased metabolism of Chlordiazepoxide caused by Probenecid.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[29]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Chlordiazepoxide and Porfimer Sodium.	Lung cancer [2C25]	[30]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Chlordiazepoxide and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[31]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Chlordiazepoxide and Lasmiditan.	Migraine [8A80]	[32]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Chlordiazepoxide and Flibanserin.	Mood disorder [6A60-6E23]	[33]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Chlordiazepoxide and Thalidomide.	Multiple myeloma [2A83]	[34]
Rifabutin	DM1YBHK	Minor	Increased metabolism of Chlordiazepoxide caused by Rifabutin mediated induction of CYP450 enzyme.	Mycobacterium infection [1B10-1B21]	[26]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Chlordiazepoxide caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[35]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Chlordiazepoxide caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[36]
Modafinil	DMYILBE	Minor	Increased metabolism of Chlordiazepoxide caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[37]
Teduglutide	DMYOAKS	Moderate	Altered absorption of Chlordiazepoxide caused by Teduglutide.	Neonatal malabsorption syndrome [KB89]	[38]
Levomethadyl Acetate	DM06HG5	Major	Additive CNS depression effects by the combination of Chlordiazepoxide and Levomethadyl Acetate.	Opioid use disorder [6C43]	[15]
Pentazocine	DM1XBHS	Major	Additive CNS depression effects by the combination of Chlordiazepoxide and Pentazocine.	Pain [MG30-MG3Z]	[10]
Dextropropoxyphene	DM23HCX	Major	Additive CNS depression effects by the combination of Chlordiazepoxide and Dextropropoxyphene.	Pain [MG30-MG3Z]	[39]
Butorphanol	DM5KYPJ	Major	Additive CNS depression effects by the combination of Chlordiazepoxide and Butorphanol.	Pain [MG30-MG3Z]	[10]
Oxymorphone	DM65AGJ	Major	Additive CNS depression effects by the combination of Chlordiazepoxide and Oxymorphone.	Pain [MG30-MG3Z]	[10]
Levorphanol	DMGS80V	Major	Additive CNS depression effects by the combination of Chlordiazepoxide and Levorphanol.	Pain [MG30-MG3Z]	[10]
Dezocine	DMJDB0Y	Major	Additive CNS depression effects by the combination of Chlordiazepoxide and Dezocine.	Pain [MG30-MG3Z]	[10]
Nalbuphine	DMOSQGU	Major	Additive CNS depression effects by the combination of Chlordiazepoxide and Nalbuphine.	Pain [MG30-MG3Z]	[10]
Buprenorphine	DMPRI8G	Major	Additive CNS depression effects by the combination of Chlordiazepoxide and Buprenorphine.	Pain [MG30-MG3Z]	[40]
Hydrocodone	DMQ2JO5	Major	Additive CNS depression effects by the combination of Chlordiazepoxide and Hydrocodone.	Pain [MG30-MG3Z]	[10]
Oxycodone	DMXLKHV	Major	Additive CNS depression effects by the combination of Chlordiazepoxide and Oxycodone.	Pain [MG30-MG3Z]	[10]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Chlordiazepoxide caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[41]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Chlordiazepoxide caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[42]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Chlordiazepoxide and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[43]
Fentanyl	DM8WAHT	Major	Additive CNS depression effects by the combination of Chlordiazepoxide and Fentanyl.	Sensation disturbance [MB40]	[10]
Armodafinil	DMGB035	Minor	Increased metabolism of Chlordiazepoxide caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[37]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Chlordiazepoxide caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[44]
Tizanidine	DMR2IQ4	Moderate	Additive CNS depression effects by the combination of Chlordiazepoxide and Tizanidine.	Tonus and reflex abnormality [MB47]	[45]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Chlordiazepoxide and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[43]
Tacrolimus	DMZ7XNQ	Moderate	Increased plasma concentrations of Chlordiazepoxide and Tacrolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[43]
Amiodarone	DMUTEX3	Minor	Potentiate the pharmacologic effects by the combination of Chlordiazepoxide and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[46]
-----------


⏷ Show the Full List of 61 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
Butylparaben	E00142	7184	Antimicrobial preservative
D&C red no. 33	E00261	19116	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
methylparaben	E00149	7456	Antimicrobial preservative
Propyl 4-hydroxybenzoate	E00141	7175	Antimicrobial preservative
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Linoleic acid	E00468	5280450	Emulsifying agent; Penetration agent; Solubilizing agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Edetate calcium disodium	E00487	6093170	Complexing agent
Ethylene glycol ethyl ether	E00164	8076	Solubilizing agent; Solvent
FD&C red no. 3	E00629	Not Available	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Gelatin	E00630	Not Available	Other agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Potassium sorbate	E00566	23676745	Antimicrobial preservative
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Sodium propionate	E00445	2723816	Antimicrobial preservative
Soybean lecithin	E00637	Not Available	Other agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent
Shellac	E00695	Not Available	Coating agent; Film/membrane-forming agent; Microencapsulating agent; Modified-release agent
--------------------


⏷ Show the Full List of 26 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Chlordiazepoxide 5 mg capsule	5 mg	Oral Capsule	Oral
Chlordiazepoxide 10 mg capsule	10 mg	Oral Capsule	Oral
Chlordiazepoxide 25 mg capsule	25 mg	Oral Capsule	Oral
Chlordiazepoxide Hydrochloride 5mg capsule	5mg	Capsule	Oral
Chlordiazepoxide Hydrochloride 25mg capsule	25mg	Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Chlordiazepoxide FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3370).
3	BDDCS applied to over 900 drugs
4	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8	Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
9	Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD "Effect of antacids on absorption of clorazepate." Clin Pharmacol Ther 22 (1977): 329-35. [PMID: 19188]
10	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
11	Cerner Multum, Inc. "Australian Product Information.".
12	Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
13	Amsden GW "Macrolides versus azalides: a drug interaction update." Ann Pharmacother 29 (1995): 906-17. [PMID: 8547740]
14	Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
15	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
16	Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
17	Gill SS, Wright EM, Reilly CS "Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study." Br J Anaesth 65 (1990): 760-5. [PMID: 2265045]
18	Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3. [PMID: 6789361]
19	Backman JT, Olkkola KT, Ojala M, Laaksovirta H, Neuvonen PJ "Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin." Epilepsia 37 (1996): 253-7. [PMID: 8598183]
20	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
21	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
22	Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
23	Abernethy DR, Greenblatt DJ, Divoll M, Moschitto LJ, Harmatz JS, Shader RI "Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam." Psychopharmacology (Berl) 80 (1983): 275-8. [PMID: 6137021]
24	Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
25	Ochs HR, Greenblatt DJ, Knuchel M "Differential effect of isoniazid on triazolam oxidation and oxazepam conjugation." Br J Clin Pharmacol 16 (1983): 743-6. [PMID: 6140941]
26	Ochs HR, Greenblatt DJ, Roberts GM, Dengler HJ "Diazepam interaction with antituberculosis drugs." Clin Pharmacol Ther 29 (1981): 671-8. [PMID: 7214796]
27	Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
28	Greenblatt DJ, vonMoltke LL, Harmatz JS, Durol ALB, Daily JP, Graf JA, Mertzanis P, Hoffman JL, Shader RI "Alprazolam-ritonavir interaction: Implications for product labeling." Clin Pharmacol Ther 67 (2000): 335-41. [PMID: 10801241]
29	Abernethy DR, Greenblatt DJ, Ameer B, Shader RI "Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation." J Pharmacol Exp Ther 234 (1985): 345-9. [PMID: 4020675]
30	Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
31	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
32	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
33	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
34	Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
35	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
36	Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
37	Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
38	Product Information. Gattex (teduglutide). NPS Pharmaceuticals, Bedminster, NJ.
39	Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
40	Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
41	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
42	Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
43	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
44	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
45	Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.
46	Kerin NZ, Aragon E, Faitel K, Frumin H, Rubenfire M "Long-term efficacy and toxicity of high- and low-dose amiodarone regimens." J Clin Pharmacol 29 (1989): 418-23. [PMID: 2661600]